Novartis said that trials showed its RTH258 drug would not need to be injected as frequently as a Regeneron rival for treating neovascular age-related macular degeneration (nAMD). nAMD is a leading cause of vision lost for people over 65-years old.
RTH258, also known as brolucizumab, worked as well as Regeneron's Eylea, with more than half of patients needing doses every 12 weeks, four weeks longer than Eyelea patients.
According to Novartis, the results have exceeded its expectations and hopes to file in 2018. Novartis also expects annual sales to exceed $1 billion.
Read the Reuters report